Acute toxicity and laxative activity of Aloe ferox resin  by Celestino, Vanessa R.L. et al.
279
ISSN 0102-695X
DOI 10.1590/S0102-695X2013005000009
Received 20 Jun 2012
Accepted 16 Sep 2012
Available online 1 Feb 2013
Revista Brasileira de Farmacognosia
Brazilian Journal of Pharmacognosy
23(2): 279-283, Mar./Apr. 2013Acute toxicity and laxative activity of Aloe 
ferox resin
Vanessa R. L. Celestino,1 Hélida M. L. Maranhão,1 Carlos F. 
B.Vasconcelos,1 Cristiano R. Lima,1 Giovanna C. R. Medeiros,1 
Alice V. Araújo,1,2 Almir G. Wanderley*,1,2
1Departamento de Ciências Farmacêuticas, Universidade Federal de Pernambuco, 
Brazil.
2Departamento de Fisiologia e Farmacologia, Universidade Federal de Pernambuco, 
Brazil.
Abstract: Aloe ferox Mill., Xanthorrhoeaceae, resin is the solid residue obtained by 
evaporating the latex that drains from the leaves transversally cut. Aloe ferox has 
been used in folk medicine as anti-inflammatory, immunostimulant, anti-bacterial, 
anti-fungal, antitumor, laxative and to heal wounds and burns. The effects of the 
oral administration of A. ferox resin (10, 25, 50, 100 and 200 mg/kg) were evaluated 
on intestinal transit in mice and its acute toxicity (5.0 g/kg) in Wistar rats. The 
hydroxyanthracene derivatives present in the resin were expressed as aloin, identified 
by thin layer chromatography and quantified by spectrophotometry. The aloin (Rf 
0.35) was identified and the percentage of hydroxyanthracene derivates expressed 
as aloin was 33.5%. A. ferox resin extract (50, 100 and 200 mg/kg) increased the 
gastrointestinal motility at a 30 min interval at 93.5, 91.8 and 93.8%, respectively, 
when compared to control group (46.5%). A single oral dose of the A. ferox resin 
extract did not induce signs of toxicity or death. Thus, the results demonstrate that A. 
ferox has laxative activity and that it is nontoxic, since LD50 could not be estimated 
and it is possibly higher than 5.0 g/kg.
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Introduction
 Aloe ferox Mill., Xanthorrhoeaceae, commercially 
known as Cape aloe, is a plant native of South Africa 
and Lesotho (Sibuyi et al., 2007). Cape aloe was a local 
traditional medicine adopted by colonists at the Cape of 
Good Hope and it was the fi rst exported product to Europe 
in the eighteenth century (Hodge, 1953; Grace et al., 2008). 
A. ferox resin is a solid residue obtained by evaporating 
latex which drains from the leaves transversally cut 
(Westendorf, 1993). It is soluble in alkalis, concentrated 
acetic acid, absolute alcohol, glycerin and hot ethanol. It 
is partially soluble in boiling water and it is practically 
insoluble in ethyl ether (Brazilian Pharmacopoeia, 2010).
 In the Brazilian folk medicine, the plant is known 
as “babosa” and the largest producers are in the states of 
São Paulo and Santa Catarina and in the Northeast region 
(Magalhães, 2005). Plants of Aloe genus have been used 
as laxative, anti-infl ammatory, immunostimulant, anti-
bacterial, anti-fungal, antitumor, hypoglycaemic, to treat 
gastric disorders and to wound and burn healing. These 
treatments are based on ethnopharmacological evidence or 
research fi ndings with Aloe vera (Loots et al., 2007) or A. 
ferox (Chen et al., 2012). 
 Miscellaneous bioactive constituents have 
been identifi ed from the leaves and roots of A. ferox. 
These components belong to different classes such as 
polysaccharides, alkaloids, anthraquinones, saccharides, 
enzymes, amino acids, inorganic mineral. However, the 
main components of Aloe are aloin, aloe-emodin and 
aloeresin (Vogler & Ernst, 1999; Eshun & He, 2004).
 One of the main biologically active 
constituents of Aloe extracts is aloin or barbaloin (10-
glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-
9(10H) - anthracenone) which is found in nature as a 
mixture of two diastereomers, aloin A (1) ((10S)-10-
glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9 
(10H)-anthracenone) and aloin B (2) ((10R)-10-
glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9 
(10H)-anthracenone) (Fanali et al., 2010).
 Aloin, a C-glycoside derivative of anthraquinone, 
may release the quinine when ingested, and the quinone 
(aloe-emodin), in turn, may accelerate the rate of ethanol 
metabolism in vivo (Chung et al., 1996). Aloeresin, a 
chromone, seems to be a potent antioxidant with the 
oxygen radical absorbance capacity of 33 and 299 higher 
than the green tea and the grape seed extracts, respectively. 
It is also well documented that aloe resin promotes an 
anti-aging effect by restoring the immune function in UV-
damaged cells (Jones et al., 2002).
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 Taking into account the commercialization 
and use of A. ferox resin in the treatment of intestinal 
constipation and that few studies has been published in 
the scientific literature about its toxicological profile, 
the aim of the present study was to evaluate the effects 
of A. ferox on intestinal transit in mice, as well as the 
safety of this use through a study of acute toxicity.
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Material and Methods
Preparation of the extract
 Aloe ferox Mill., Xanthorrhoeaceae, resin was 
prepared by cutting transversely the leaf near the base 
and taking it inclined so that the latex contained in the 
specialized pericyclic cells and sometimes in the adjacent 
parenchyma flowed out in about 6 h. A slow evaporation, 
carried out in an appropriate temperature of 45º C in a 
incubator for 6 h, produced an opaque mass, with a wax-
like fracture. The resin used in the current study was a 
commercial preparation produced and kindly donated by 
Odaly Soares Pharmaceutical Laboratory, Ceará, Brazil, 
used in a medicine registered in Anvisa number 105190028. 
In previous analysis in our laboratory concerning the resin 
solubility, the glycerin was the solvent that showed better 
solubility and compatibility with in vivo experiments. 
The resin was crushed in automatic processor and it was 
solubilized in 40% glycerin (Vetec®) (v/v). 
Drugs
 Physostigmine (eserine salicylate salt) was 
purchased from Sigma-Aldrich (USA). 
Quantification of hydroxyanthracene derivates by UV-
Vis spectrophotometry
 
 Powdered sample (400 mg) was put in a 250 mL 
Erlenmeyer flask, together with 2 mL of methanol and 5 
mL of water previously heated (60 ºC). The components 
were mixed and 75 mL of the same water was added and 
stirred for 30 min. After cooling, the solution was filtered 
and transferred to a volumetric flask and its volume was 
completed to 1000 mL. Then, 10 mL of this solution was 
added in a round bottom flask containing 1 mL of a solution 
60% ferric chloride (w/v) and 6 mL of hydrochloric acid. 
The solution was heated in a water bath under reflux for 4 h 
and, after cooling, it was transferred to a dropping funnel. 
After successive washing with polar and apolar solvents, 
the organic phase was collected for UV-analysis. The UV 
absorption spectrum was obtained in the wavelength range 
from 200 to 600 nm (50 UV-Vis Spectrophotometer), using 
the methanol as the compensation liquid. The specific 
absorbance of aloe-emodin, obtained by oxidation of 
aloin, is at 512 nm. The assay was performed in triplicate. 
The percentage of hydroxyanthracene derivates expressed 
as aloin was calculated from the expression (Brazilian 
Pharmacopoeia, 2010).
HAD=A x 19.6/m
where: HAD; hydroxyanthracene derivates (%); A: 
absorbance at 512 nm; m: mass of the substance 
examined in grams.
Identification of aloin by thin layer chromatography
 In 250 mg of the powdered sample, it was 
added 20 mL of methanol and the solution was heated 
up to boiling.10 μL of this solution were applied silica 
gel plates (Merck® art. 105553, UV 250-366 nm). After 
drying, the plate was eluated with water-methanol-ethyl 
acetate (13:17:100 v/v). The plate was allowed to dry in 
air, sprayed with 100 g/L solution of potassium hydroxide 
in methanol. The retention factor (Rf) was obtained and the 
plate was examined in ultraviolet light at 365 nm. It was 
used an aloin solution as reference standard (Gutterman & 
Chauser-Volfson, 2000; Brazilian Pharmacopoeia, 2010).
Animals
 Adult female and male Wistar rats (Rattus 
norvegicus var. albinus), aged three months and weighing 
180-200 and 240-260 g, respectively, and male Swiss albino 
mice (Mus musculus), 6-8 weeks of age, weighing between 
25-35 g were obtained respectively from Department of 
Physiology and Pharmacology and from Aggeu Magalhães 
Laboratory at the Federal University of Pernambuco. 
The animals were maintained in standard environmental 
conditions (22±2 ºC; 12:12 h dark/light cycle). Water and 
chow (Labina®, Purina, Brazil) were available ad libitum. 
The experimental protocol was approved by the Animal 
Experimentation Ethics Committee of UFPE (Process no. 
007340), in accordance with the National Institute of Health 
Guide for the Care and Use of Laboratory Animals.
Experimental protocol
 Acute toxicity
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 “Up and down” acute toxicity studies were 
performed in rats of both sexes as described by OECD 
(2001), with slight modifications. The animals were 
randomly divided into four groups (n=4/group/sex) and 
deprived of feed for 12 h with access to water ad libitum. 
The treated groups received A. ferox resin in a single dose 
of 5 g/kg, by oral route, and the control groups received 
a same volume of vehicle (40% glycerin solution - v/v). 
The observations were performed at 30, 60, 120, 180 and 
240 min after the oral treatment and daily for fourteen 
days. Behavioral changes (piloerection, tremors, sedation, 
loss of corneal reflex, motor activity), weight, food and 
water intake, clinical signs of toxicity and mortality were 
recorded daily (Malone, 1977).
 Gastrointestinal motility test
 The intestinal transit of A. ferox resin was 
evaluated in mice using the method of Stickney & Northup 
(1959). Mice fasted for 16 h were randomly divided into 
eight groups (n=8/group). G1-control group (received 
water), G2-received vehicle (40% glycerin solution - v/v), 
G3-received physostigmine 0.001 mg/kg, G4-G8-resin 
extract of A. ferox (Af) at doses of 10, 25, 50, 100 and 200 
mg/kg, respectively. The treatments were administered 
orally by gavage in a single dose. After 60 min of the 
treatments, a 10% activated charcoal solution was given 
orally (0.1 mL/10 g b.w.) to all groups and, after 30 min 
of this administration, the mice were killed. The small 
intestines were removed and their length was measured 
from the pyloric sphincter to the ileocaecal junction. The 
distance traversed by activated charcoal (it was considered 
the last portion of the small intestine that showed at least 
one centimeter continuous of the marker) was recorded 
as a percentage of the total length of the small intestine 
(gastrointestinal transit percent).
Statistical analysis
 Statistical analyses were performed by using the 
software GraphPad Prism 5®. The results were expressed 
as mean value±SEM. The differences between control and 
treated groups were compared using one-way ANOVA 
followed, when necessary, by Dunnett’s test. A probability 
level of less than 5% (p<0.05) was considered significant.
 To the intestinal transit protocol, a concentration-
effect curve was constructed by subtracting the values of 
the control group from the treated groups and the ED50 
was calculated using the nonlinear regression by the 
software GraphPad Prism 5®.
Results
Aloin identification and quantification
 The chromatogram obtained with the solution test 
showed in the central part a zone of yellow fluorescence 
(aloin-Rf 0.35) similar in position to the zone corresponding 
to aloin in the chromatogram obtained with the reference 
solution. The percentage of hydroxyanthracene derivates 
expressed as aloin was 33.5%.
Acute toxicity
 It was observed that Aloe ferox resin (5.0 g/kg, 
p.o.) induced moderate diarrhea and reduced motor activity 
at the first hour of observation. However, the animals 
treated with the same volume of vehicle (40% glycerin 
solution-v/v) did not show these symptoms in any time 
of the experiment. The A. ferox resin produced no sign of 
acute toxicity or death in the treated animals. No significant 
changes in food and water intake or body weight were 
observed during the fourteen days of observation (data not 
shown). Therefore, the LD50 could not be estimated and it 
is possibly higher than 5.0 g/kg.
0
25
50
75
100
125
25 100 200 0.001 (mg/kg)
physostigmineAloe ferox resin
* * * *
5010
Control
V
In
te
st
in
al
 tr
an
si
t (
%
)
Figure 1. Effect of the oral administration of Aloe ferox resin 
on gastrointestinal motility in mice (n=8/group). Groups: 
control (water), vehicle (V, 40% glycerin solution), Aloe 
ferox resin (10 to 200 mg/kg) and physostigmine (0.001 mg/
kg). The results were expressed as mean±SEM. The ordinates 
indicate the percentage of distance traveled by the marker 
(activated charcoal) in relation to the total length of the small 
intestine (intestinal transit) 30 min after ingestion of the 
marker. *Statistically different from control group (ANOVA 
followed by Dunett's test, p<0.05).
Gastrointestinal motility 
 The results of the gastrointestinal motility 
test are shown in the Figure 1. A. ferox resin extract 
at doses of 50, 100 and 200 mg/kg induced significant 
increase of the gastrointestinal motility at 30 min of 
93.5, 91.8 and 93.8%, respectively, in relation to control 
group (46.5%). As expected, the group treated with 
physostigmine (0.001 mg/kg) significantly potentiated 
(91.2%) the intestinal transit, with a estimated ED50 
of 19,1 mg/kg. As it was observed, the groups treated 
with A. ferox resin and physostigmine increased about 
two times the distance traveled by the marker when 
compared to vehicle and control groups.
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Discussion
 The use of herbal remedies in the treatment of 
constipation is a common practice in many countries 
of the world (Kim, 2005). The constipation is the most 
common gastrointestinal complaint being a risk factor of 
colorectal cancer. The pathophysiological mechanisms 
that could explain the constipation are reduction of the 
colonic transit speed (colonic inertia) and difficulty of 
removing the faeces due to functional changes of the 
pelvic floor, rectum or anus (Lennard-Jones, 2002).
 In Brazil, Aloe ferox Mill., Xanthorrhoeaceae, 
resin is widely used in the ethnomedicine as laxative, 
particularly by women during pregnancy (Bradley, 1992; 
Akao et al., 1996). However, there is little scientific 
information to support this hypothesis. Therefore, the 
study was designed to evaluate the effects of the oral 
administration of A. ferox resin on gastrointestinal motility 
in mice and its safety of use in rats Wistar.
 The laxative effect of Aloe species is due to the 
presence of anthranoid glycosides derivates, mainly aloin 
(Bradley, 1992; Akao et al., 1996). These derivates were 
quantified in the A. ferox resin (33.5%) and they could 
explain the increased intestinal transit in the animals treated 
with the highest doses of A. ferox. According to Brazilian 
Pharmacopoeia (2010), A. ferox resin consists of at least 
18% hydroxyanthracene derivates expressed as aloin and 
Costa (1975) has reported that this level can reach 40%.
 The intestinal transit measurement model 
in mice has been used to prove the effectiveness 
of laxatives and it showed to be suitable for this 
purpose (Mesia-Vela et al., 2004). The treatment with 
A. ferox resin (50, 100 e 200 mg/kg, b.w.) showed 
evident laxative effect 30 min after its administration, 
supporting its ethnomedicinal use. In fact, Wintola et 
al. (2010) recently showed that oral administration 
of the leaves aqueous extract of A. ferox, in the same 
doses, exhibited laxative activity on constipated rats 
induced by loperamide. In our study, activated charcoal 
solution was used as a marker to measure the intestinal 
transit. Its propulsion through the gastrointestinal tract 
did not differ significantly between the groups treated 
with A. ferox resin (10 and 25 mg/kg, b.w.) and the 
control and vehicle groups. Although the glycerin, 
used as vehicle, is considered an osmotic laxative 
by producing water retention in the intestinal lumen, 
stimulating the secretion of fluid and intestinal motility 
(Fuchs et al., 2004), it was not observed increased 
peristaltic activity in the group treated with vehicle 
alone when compared to control. As expected, since 
the standard drug physostigmine (an anticholinesterase 
agent) inhibits the enzyme acetylcholinesterase and 
therefore augments the concentration of acetylcholine, 
it accelerated the intestinal transit.
 The increase in intestinal motility may be due 
to the presence of anthranoid glycosides derivatives, of 
which aloin is the main compound (Ishii et al., 1994). 
According to Bradley (1992) and Akao et al. (1996), 
after oral administration, the aloin is not absorbed in 
the upper intestine, it is hydrolyzed in the colon by 
Eubacterium sp. and then reduced to active metabolite 
aloe-emodinanthrone. This one stimulates colonic 
motility, augmenting propulsion and accelerating 
colonic transit, which reduces fluid absorption from the 
fecal mass. It also increases paracellular permeability 
across the colonic mucosa probably owing to an 
inhibition of (Na++K+)-ATPase or an inhibition of 
chloride channels, which results in an increase in the 
water content in the large intestine (Witte, 1993). Aloe-
emodin stimulates the release of Platelet-Activating 
Factor (PAF) in human ileal and colonic mucosa 
contributing to the laxative effect of Aloe (Tavares et 
al., 1996). Izzo et al. (1999) also studied the role of 
oxide nitric (NO) on aloe-induced diarrhea in the rats. 
The results suggested that inhibition of basal calcium-
dependent NO synthesis activity by aloe could reduce 
its diarrheal effect.
 Moreover, the acute toxicity study did not show 
any toxic symptoms, changes in behavior or mortality at 
the dose of 5.0 g/kg. According to Kennedy et al. (1986), 
substances that present LD50 higher than 5 g/kg, by oral 
route, can be considered practically nontoxic. Therefore, 
it can be suggested that acute toxicity of the A. ferox resin 
is low by oral route.
 In conclusion, our results showed that the 
A. ferox resin extract increases the gastrointestinal 
motility, proving its laxative action. In addition, revealed 
to be nontoxic, when oral acute administration was 
performed. However, chronic and reproductive toxicities, 
mutagenicity and others carcinogenicity studies are 
necessary to further support the safety of use.
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